“Micronuclei and Disease” special issue: Aims, scope, and synthesis of outcomes
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
“Micronuclei and Disease” special issue : Aims, scope, and synthesis of outcomes. / Fenech, Michael; Knasmueller, Siegfried; Knudsen, Lisbeth E.; Kirsch-Volders, Micheline; Deo, Permal; Franzke, Bernhard; Stopper, Helga; Andreassi, Maria Grazia; Bolognesi, Claudia; Dhillon, Varinderpal S.; Laffon, Blanca; Wagner, Karl Heinz; Bonassi, Stefano.
I: Mutation Research - Reviews in Mutation Research, Bind 788, 108384, 2021.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - “Micronuclei and Disease” special issue
T2 - Aims, scope, and synthesis of outcomes
AU - Fenech, Michael
AU - Knasmueller, Siegfried
AU - Knudsen, Lisbeth E.
AU - Kirsch-Volders, Micheline
AU - Deo, Permal
AU - Franzke, Bernhard
AU - Stopper, Helga
AU - Andreassi, Maria Grazia
AU - Bolognesi, Claudia
AU - Dhillon, Varinderpal S.
AU - Laffon, Blanca
AU - Wagner, Karl Heinz
AU - Bonassi, Stefano
N1 - Publisher Copyright: © 2021 The Authors
PY - 2021
Y1 - 2021
N2 - The purpose of the “Micronuclei and Disease” special issue (SI) is to: (i) Determine the level of evidence for association of micronuclei (MN), a biomarker of numerical and structural chromosomal aberrations, with risk of specific diseases in humans; (ii) Define plausible mechanisms that explain association of MN with each disease; (iii) Identify knowledge gaps and research needed to translate MN assays into clinical practice. The “MN and Disease” SI includes 14 papers. The first is a review of mechanisms of MN formation and their consequences in humans. 11 papers are systematic reviews and/or meta-analyses of the association of MN with reproduction, child health, inflammation, auto-immune disease, glycation, metabolic diseases, chronic kidney disease, cardiovascular disease, eleven common cancers, ageing and frailty. The penultimate paper focuses on effect of interventions on MN frequency in the elderly. A road map for translation of MN data into clinical practice is the topic of the final paper. The majority of reviewed studies were case-control studies in which the ratio of mean MN frequency in disease cases relative to controls, i.e. the mean ratio (MR), was calculated. The mean of these MR values, estimated by meta-analyses, for lymphocyte and buccal cell MN in non-cancer diseases were 2.3 and 3.6 respectively, and for cancers they were 1.7 and 2.6 respectively. The highest MR values were observed in studies of cancer cases in which MN were measured in the same tissue as the tumour (MR = 4.9–10.8). This special issue is an important milestone in the evidence supporting MN as a reliable genomic biomarker of developmental and degenerative disease risk. These advances, together with results from prospective cohort studies, are helping to identify diseases in which MN assays can be practically employed in the clinical setting to better identify high risk patients and to prioritise them for preventive therapy.
AB - The purpose of the “Micronuclei and Disease” special issue (SI) is to: (i) Determine the level of evidence for association of micronuclei (MN), a biomarker of numerical and structural chromosomal aberrations, with risk of specific diseases in humans; (ii) Define plausible mechanisms that explain association of MN with each disease; (iii) Identify knowledge gaps and research needed to translate MN assays into clinical practice. The “MN and Disease” SI includes 14 papers. The first is a review of mechanisms of MN formation and their consequences in humans. 11 papers are systematic reviews and/or meta-analyses of the association of MN with reproduction, child health, inflammation, auto-immune disease, glycation, metabolic diseases, chronic kidney disease, cardiovascular disease, eleven common cancers, ageing and frailty. The penultimate paper focuses on effect of interventions on MN frequency in the elderly. A road map for translation of MN data into clinical practice is the topic of the final paper. The majority of reviewed studies were case-control studies in which the ratio of mean MN frequency in disease cases relative to controls, i.e. the mean ratio (MR), was calculated. The mean of these MR values, estimated by meta-analyses, for lymphocyte and buccal cell MN in non-cancer diseases were 2.3 and 3.6 respectively, and for cancers they were 1.7 and 2.6 respectively. The highest MR values were observed in studies of cancer cases in which MN were measured in the same tissue as the tumour (MR = 4.9–10.8). This special issue is an important milestone in the evidence supporting MN as a reliable genomic biomarker of developmental and degenerative disease risk. These advances, together with results from prospective cohort studies, are helping to identify diseases in which MN assays can be practically employed in the clinical setting to better identify high risk patients and to prioritise them for preventive therapy.
KW - Ageing
KW - Cancer
KW - Cardiovascular disease
KW - Disease
KW - Inflammation
KW - Micronuclei
U2 - 10.1016/j.mrrev.2021.108384
DO - 10.1016/j.mrrev.2021.108384
M3 - Review
C2 - 34893149
AN - SCOPUS:85108012110
VL - 788
JO - Mutation Research - Reviews
JF - Mutation Research - Reviews
SN - 1383-5742
M1 - 108384
ER -
ID: 283735616